RISPERIDONE

Information current as at: 1 August 2025

PBAC meeting date: March 2023
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Okedi®
Pharmaceutical company:
Maxx Pharma Pty Ltd
Condition/indication:
(therapeutic use)
  • Schizophrenia
PBAC Submission type:
New PBS listing (–)
Comment:
To be considered at a future PBAC meeting
Related medicines:
--

Progress Details

Submission received for:
March 2023 PBAC meeting
Opportunity for consumer comment:
Open 23/11/2022 and close 25/01/2023 (see PBS Website)
PBAC meeting:
Held on 08/03/2023
PBAC outcome published:
Not Applicable (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable

Case ID: a668

Page last updated: 30 June 2025

v.9.18